

Philipp Erben

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6357592/publications.pdf>

Version: 2024-02-01

128
papers

5,742
citations

87843

38
h-index

82499

72
g-index

134
all docs

134
docs citations

134
times ranked

5651
citing authors

#	ARTICLE	IF	CITATIONS
1	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	0.6	400
2	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). <i>Leukemia</i> , 2012, 26, 2096-2102.	3.3	383
3	Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Journal of Clinical Oncology</i> , 2009, 27, 4204-4210.	0.8	292
4	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting <i>BCR-ABL</i> mutations. <i>Blood</i> , 2009, 114, 4944-4953.	0.6	271
5	Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood</i> , 2013, 122, 2460-2466.	0.6	222
6	Harmonization of molecular monitoring of CML therapy in Europe. <i>Leukemia</i> , 2009, 23, 1957-1963.	3.3	196
7	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in <i>FIP1L1-PDGFRα</i> -positive chronic eosinophilic leukemia. <i>Blood</i> , 2007, 109, 4635-4640.	0.6	195
8	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3472-3479.	0.8	181
9	Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1429-1435.	0.8	153
10	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	1.6	148
11	The <i>KIT</i> D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. <i>Annals of Hematology</i> , 2014, 93, 81-88.	0.8	142
12	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in <i>BCR/ABL</i> + progenitors via <i>JAK-2/STAT-5</i> pathway activation. <i>Blood</i> , 2007, 109, 2147-2155.	0.6	135
13	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome â€” a phase III study. <i>British Journal of Haematology</i> , 2008, 143, 707-715.	1.2	128
14	Velocity of early <i>BCR-ABL</i> transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. <i>Leukemia</i> , 2014, 28, 1988-1992.	3.3	126
15	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. <i>Cancer</i> , 2010, 116, 3852-3861.	2.0	115
16	Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1487-1493.	0.4	104
17	Harmonization of <i>BCR-ABL</i> mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. <i>Leukemia</i> , 2008, 22, 96-102.	3.3	100
18	Dynamics of <i>BCR-ABL</i> mutated clones prior to hematologic or cytogenetic resistance to imatinib. <i>Haematologica</i> , 2008, 93, 186-192.	1.7	98

#	ARTICLE	IF	CITATIONS
19	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <i>Haematologica</i> , 2014, 99, 1441-1447.	1.7	97
20	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011, 117, 2935-2943.	0.6	76
21	Response of ETV6-FLT3 ^{ITD} positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. <i>Blood</i> , 2011, 118, 2239-2242.	0.6	75
22	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	1.3	75
23	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and aCDK5RAP2-PDGFRB fusion gene. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 950-956.	1.5	72
24	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. <i>Lancet Oncology</i> , The, 2007, 8, 658-660.	5.1	72
25	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. <i>Haematologica</i> , 2010, 95, 738-744.	1.7	72
26	Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. <i>Archives of Dermatology</i> , 2007, 143, 736-40.	1.7	71
27	TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. <i>Haematologica</i> , 2010, 95, 20-26.	1.7	63
28	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 267-274.	1.4	58
29	Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 998-1008.	2.5	58
30	Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRB positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. <i>Leukemia</i> , 2012, 26, 162-164.	3.3	55
31	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 403-412.	2.0	54
32	Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 41-52.	0.8	53
33	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1389-1393.	1.7	48
34	Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. <i>Annals of Hematology</i> , 2013, 92, 1345-1350.	0.8	47
35	KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1032-1038.	0.4	46
36	miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection Markers. <i>Cancers</i> , 2020, 12, 43.	1.7	46

#	ARTICLE	IF	CITATIONS
37	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
38	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica, 2008, 93, 765-769.	1.7	41
39	Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer, 2011, 11, 363.	1.1	40
40	Identification of a <i>MYO18A</i> – <i>PDGFRB</i> fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33;q11.2). Genes Chromosomes and Cancer, 2009, 48, 179-183.	1.5	35
41	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. International Journal of Molecular Sciences, 2018, 19, 3396.	1.8	35
42	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
43	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 2018, 8, 14383.	1.6	32
44	Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1965-1969.	1.2	31
45	RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells. International Journal of Oncology, 2017, 50, 920-932.	1.4	31
46	ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urologia Internationalis, 2017, 98, 282-289.	0.6	30
47	Interferon Alpha 2a (IFN) Maintenance Therapy After Imatinib Plus IFN Induction Therapy in Chronic Myeloid Leukemia (CML) Induces Stable Long-Term Molecular Remissions and Is Associated with Increased Proteinase 3 (PR3) Expression and the Presence of PR1-Specific T-Cells.. Blood, 2009, 114, 647-647.	0.6	30
48	Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anti-Cancer Drugs, 2009, 20, 519-524.	0.7	29
49	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Annals of Hematology, 2012, 91, 1713-1720.	0.8	29
50	HERV-E-Mediated Modulation of PLA2G4A Transcription in Urothelial Carcinoma. PLoS ONE, 2012, 7, e49341.	1.1	29
51	ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 547-552.	1.4	25
52	The molecular anatomy of the FIP1L1-PDGFR α fusion gene. Leukemia, 2009, 23, 271-278.	3.3	23
53	Identification and functional characterization of imatinib-sensitive <i>DTD1</i> – <i>PDGFRB</i> and <i>CCDC88C</i> – <i>PDGFRB</i> fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes Chromosomes and Cancer, 2014, 53, 411-421.	1.5	23
54	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Translational Oncology, 2017, 10, 340-345.	1.7	22

#	ARTICLE	IF	CITATIONS
55	Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. <i>Oncotarget</i> , 2018, 9, 25935-25945.	0.8	22
56	MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. <i>Leukemia</i> , 2014, 28, 1478-1485.	3.3	20
57	Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. <i>Translational Oncology</i> , 2018, 11, 467-476.	1.7	19
58	FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 187-196.	1.3	19
59	The FIP1L1-PDGFR fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia. <i>Blood</i> , 2014, 123, 595-597.	0.6	18
60	The EEF1A2 gene expression as risk predictor in localized prostate cancer. <i>BMC Urology</i> , 2017, 17, 86.	0.6	18
61	Cause and management of therapy resistance. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 367-379.	0.7	17
62	mRNA Expression of Platelet-Derived Growth Factor Receptor- β and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1544-1550.	0.4	16
63	SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 756-767.	1.5	16
64	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 248-256.e2.	0.9	16
65	Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. <i>Urologia Internationalis</i> , 2018, 100, 122-125.	0.6	16
66	FOXM1 predicts disease progression in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1701-1709.	1.2	16
67	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019, 12, 661-668.	1.7	16
68	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <i>Oncotarget</i> , 2017, 8, 47595-47606.	0.8	16
69	Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. <i>Oncotarget</i> , 2017, 8, 67684-67695.	0.8	16
70	ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data. <i>Cancers</i> , 2019, 11, 1840.	1.7	15
71	Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β -catenin expression. <i>Anticancer Research</i> , 2014, 34, 7061-9.	0.5	15
72	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 167, 13-22.	1.3	15

#	ARTICLE	IF	CITATIONS
73	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 994.	1.0	14
74	Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2016, 36, 5205-5214.	0.5	13
75	Microvascular Invasion of Testicular Nonseminomatous Germ Cell Tumors: Implications of Separate Evaluation of Lymphatic and Blood Vessels. <i>Journal of Urology</i> , 2014, 192, 593-599.	0.2	12
76	Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. <i>World Journal of Urology</i> , 2020, 38, 637-645.	1.2	12
77	Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 3216-3216.	0.6	12
78	Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-R α expression in squamous cell carcinoma of the head and neck in vitro. <i>International Journal of Oncology</i> , 2011, 38, 1001-12.	1.4	11
79	Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7. <i>Bladder Cancer</i> , 2018, 4, 67-75.	0.2	11
80	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 288.	3.5	11
81	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1985-1993.	1.2	10
82	Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 145-153.e5.	0.9	10
83	Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 209-217.	1.4	10
84	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6567-6578.	0.9	10
85	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV. <i>Blood</i> , 2008, 112, 333-333.	0.6	10
86	Annexin and Survivin in Locally Advanced Rectal Cancer: Indicators of Resistance to Preoperative Chemoradiotherapy?. <i>Onkologie</i> , 2010, 33, 439-444.	1.1	9
87	IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status. <i>Advances in Urology</i> , 2014, 2014, 1-6.	0.6	9
88	Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β -catenin expression. <i>Oncology Letters</i> , 2016, 11, 2715-2724.	0.8	9
89	POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer. <i>Translational Oncology</i> , 2021, 14, 100900.	1.7	9
90	Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β -subunit c of cytokine receptors. <i>Leukemia</i> , 2012, 26, 1321-1328.	3.3	8

#	ARTICLE	IF	CITATIONS
91	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	1.7	8
92	Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy. <i>Anticancer Research</i> , 2022, 42, 1911-1918.	0.5	8
93	Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 203-212.	1.2	7
94	Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1260-1265.	0.5	7
95	Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer. <i>Genes</i> , 2021, 12, 550.	1.0	7
96	The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 10926.	1.6	7
97	Suitability of the PAXgene [®] system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 318-22.	1.4	6
98	Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. <i>Oncology Reports</i> , 2011, 25, 1145-51.	1.2	6
99	Chemotherapeutic alteration of β -catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. <i>Oncology Reports</i> , 2011, 27, 270-80.	1.2	6
100	Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-R α / β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. <i>Oncology Reports</i> , 2011, 26, 1099-109.	1.2	6
101	RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4188.	1.8	6
102	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. <i>Urology</i> , 2021, 157, 93-101.	0.5	6
103	Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2022, 81, 606-614.	0.9	6
104	Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma. <i>Oncology Reports</i> , 2012, 28, 172-8.	1.2	5
105	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 473.	1.1	5
106	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	0.8	5
107	Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 530.e19-530.e27.	0.8	4
108	Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4373.	1.8	4

#	ARTICLE	IF	CITATIONS
109	A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer. <i>PLoS ONE</i> , 2021, 16, e0248342.	1.1	4
110	Prostate cancer transfection by acoustic energy using pEGFP-N1 as reporter gene in the solid Dunning R-3327-MatLu tumor. <i>Prostate Cancer and Prostatic Diseases</i> , 2003, 6, 290-293.	2.0	3
111	Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 411-417.	1.2	3
112	Novel insights into a reputedly irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy. <i>World Journal of Urology</i> , 2017, 35, 1701-1711.	1.2	3
113	Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 627-633.	0.8	3
114	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. <i>Life</i> , 2021, 11, 642.	1.1	3
115	Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group. <i>Blood</i> , 2011, 118, 425-425.	0.6	3
116	The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemia. <i>Annals of Hematology</i> , 2011, 90, 389-394.	0.8	2
117	Prognostic Impact of mRNA Expression Levels of HER1/4 (ERBB1/4) in Patients with Locally Advanced Rectal Cancer. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	2
118	MMP9, Cyclin D1 and β -Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. <i>Anticancer Research</i> , 2015, 35, 3801-10.	0.5	2
119	Molecular Analysis of Desmoid Tumors with a High-Density Single-Nucleotide Polymorphism Array Identifies New Molecular Candidate Lesions. <i>Oncology Research and Treatment</i> , 2012, 35, 684-689.	0.8	1
120	Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. <i>Annals of Hematology</i> , 2013, 92, 907-915.	0.8	1
121	Impact of Altered WNT2B Expression on Bladder Wall Fibroblasts: Implications for Apoptosis Regulation in the Stroma of the Lower Urinary Tract. <i>Urologia Internationalis</i> , 2017, 99, 476-483.	0.6	1
122	Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 20472.	1.6	1
123	Factors to improve academic publishing success of physicians engaged in scientific research. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2021, 162, 63-69.	0.7	1
124	High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 499.e1-499.e8.	0.8	1
125	Prognostic value of HER2 expression in patients with bladder cancer treated with radical cystectomy: A biomarker study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15515-e15515.	0.8	1
126	Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a NanoString based molecular screening.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4525-4525.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section. <i>Urologia Internationalis</i> , 2022, 106, 816-824.	0.6	1
128	High Density SNP Array Analysis of Acute Promyelocytic Leukemia (APL) Detects New Common Genomic Copy Number Alterations as Possible Cooperating Lesions. <i>Blood</i> , 2010, 116, 2721-2721.	0.6	0